Predicting Flare in Patients With Rheumatoid Arthritis in Biologic Induced Remission, on Tapering, and on Stable...

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Biologic disease-modifying antirheumatic drug (b-DMARD) therapy is common for rheumatoid arthritis (RA) patients in stable remission.
• Current guidelines lack specific strategies for successfully tapering b-DMARDs in RA patients.
• Identifying predictors of flare is crucial for managing RA treatment withdrawal.

Purpose of the Study:

• To identify predictors of disease flare in rheumatoid arthritis (RA) patients undergoing stable b-DMARD therapy tapering.
• To compare flare rates between patients tapering b-DMARDs and those on stable treatment.
• To evaluate the role of clinical, ultrasound, immunological, and patient-reported outcomes in predicting flare.

Main Methods:

• Patients with RA in sustained remission (DAS28-CRP <2.6 for ≥6 months) were recruited.
• Data collected included clinical assessments, ultrasound (US) with power Doppler (PD), CD4+ T cell subsets, and patient-reported outcomes (PROs).
• Logistic regression identified flare predictors; risk stratification used AUROC analysis.

Main Results:

• Flare occurred in 37% of patients tapering b-DMARDs versus 20% on stable treatment (P=0.043).
• In the tapering group, flare was associated with lower regulatory T cells (Tregs) and elevated CRP, ESR, and inflammation-related cells (IRCs).
• Predictive models for flare in the tapering group included Tregs, IRCs, and CRP (81.7% accuracy); in the continued therapy group, tender joint count, US PD, and pain scores were predictive (82.1% accuracy).

Conclusions:

• Lower Tregs and elevated inflammation biomarkers (IRCs/CRP) predict flare during b-DMARD tapering in RA.
• Pain parameters and ultrasound inflammation predict flare in patients continuing b-DMARD therapy.
• Biomarker knowledge can optimize b-DMARD tapering selection and guide monitoring for patients on continued therapy.